Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peter Impey

- PMLiVE

Bristol Myers Squibb shares positive results for Opdivo combination in advanced liver cancer

HCC is the most common primary liver cancer, accounting for 90% of all cases of liver cancer

- PMLiVE

Headwinds loom for pharma web strategy

Online changes pose some pressing questions for the industry and demand a new approach to websites and data

Global Health Beat – UK

The Global Health Beat kicks off with Amanda Preto, VP, Marketing, and Matt Durham, Director, Global Media, joined by Henry Carter, VP, Global, Medscape, and Marc Clifford, Commercial Digital Lead,...

CMI Media Group

- PMLiVE

Revolutionising healthcare: The crucial role of diagnostics in transforming the NHS

Amid the formidable challenges faced by the NHS, Onyx Health delve into the pivotal role of diagnostics in healthcare transformation, showcasing how collaboration, innovation, and patient-centric approaches are revolutionising healthcare...

Onyx Health

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Novartis’ Fabhalta recommended by CHMP to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Women in pharma

Sanofi’s Rippon Ubhi on her new role as Country Lead for UK & Ireland

- PMLiVE

FDA approves Italfarmaco’s Duvyzat as first nonsteroidal Duchenne muscular dystrophy drug

The neuromuscular genetic disease is estimated to affect one in every 3,500 to 6,000 male births worldwide

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links